MEDPACE

CARDIOVASCULAR

Experts. Experience. Execution.

Discover the POWER OF X™



The Power of X in Cardiovascular

Experts:

- As a key therapeutic area since Medpace's inception, Medpace project teams are well-versed in the complications and regulatory issues associated with cardiovascular indications
- Medpace medical monitors are involved in your studies from protocol design though submission
- Member of the Scientific Oversight Committee of the Cardiac Safety Research Consortium

Experience:

- Conducted over 300 trials
- Includes phase I-IV in both pharmaceutical and device
- Experience in over 45 countries
- Nearly 30% of current ongoing projects
- Acute care settings
- Managed large outcome studies
- Managed Clinical Endpoint Committee (CEC) and adjudication process for numerous studies

Execution:

- Full-service approach to drug development - visit medpace.com for a list of comprehensive services
- Strong relationships with key industry investigative sites and KOLs
- Clintrak® study management tool provides IVRS/IWRS, study, data, laboratory, and image management, as well as endpoint adjudication
- ECG Core Lab
- Cardiac safety including TQT studies

Cardiovascular trials present a unique set of challenges. Partner with a specialty team with noted experts, experience and execution.

Medpace has conducted hundreds of cardiovascular trials and has helped pioneer many of the preventative cardiovascular compounds and devices introduced in the last 15 years. Our experience with global regulatory authorities, coupled with early planning and collaboration, accelerates your path to approval.

Regulatory and Therapeutic Strength:

Medpace is home to renowned regulatory and therapeutic experts who are committed to the complex and intertwined therapeutic areas of cardiology. Our regulatory experts are former government officials who have invaluable insight into cardiovascular drug and medical device approvals. They are an integral part of every study and their valuable guidance ensures every step efficiently accelerates the approval process.

Therapeutic Categories

- Acute coronary syndrome
- Coronary artery disease
- Hypertension
- Stroke
- Heart failure
- Atherosclerosis
- STEMI and non-STEMI

MEDPACE

Site Identification and Feasibility:

Cardiovascular research often calls for high study enrolment which may lead to competition for investigators and patients. Medpace is unique in the industry in terms of its many long-term relationships with key Investigators and opinion leaders worldwide that specialize in cardiovascular trials. The Investigators, many of whom are renowned scientists and opinion leaders in the field, are well-known to the Medpace Medical Monitors and operations staff since they have worked with us for many years. These relationships facilitate more accurate assessments of whether the objectives of a study can be met within the proposed timelines. The rationale for the study design and, importantly, the proposed eligibility criteria are discussed directly with Investigators. This leads to greater involvement of the Investigators in the conduct of the study, which translates to better recruitment and study management.

Large Cardiovascular Endpoint Trials:

The ability to integrate cardiovascular trials with metabolic/endocrinology projects across both therapeutic and regulatory knowledge bases provides sponsors with unique capabilities for large studies demanding rigorous safety requirements. Electronic endpoint adjudication capabilities coupled with strategic consultation and management of all outcomes and regulatory requirements, keeps projects on track.

Cardiac Safety:

In addition to full-service CRO functionality, Medpace's capabilities include core laboratory services in ECG technologies. The Medpace ECG Core Laboratory provides sponsors with reliable, consistent, and prompt electrocardiographic services in support of global clinical development programs to support international Phase I–IV clinical trials. With the intense focus on cardiac safety from regulatory authorities, Medpace also has the integrated services and experts to manage the rigors of TQT studies.

Medical Device:

Medpace Medical Device (MMD) is a wholly-owned division of Medpace exclusively dedicated to the design and conduct of medical device trials. MMD has vast experience in cardiovascular trials including:

- Coronary, Peripheral and Carotid Stents
- Aortic Valve Replacement
- RF Ablation for A-fib
- Endovascular interventions
- ICD/CRT-D and Pacemakers
- LVAD

Drug/Device Combinations:

With an unparalleled record of success with cardiovascular medical device and drug studies, Medpace and MMD bring a new level of integration to cardiovascular studies with the ability to combine drug and device trials for efficient innovation in cardiovascular treatments.

Who We Are

Medpace is a global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug and device development services.